Last reviewed · How we verify

Intravenous acetazolamide

National University Hospital, Singapore · FDA-approved active Small molecule

Intravenous acetazolamide is a Carbonic anhydrase inhibitor Small molecule drug developed by National University Hospital, Singapore. It is currently FDA-approved for Glaucoma and ocular hypertension, Acute mountain sickness, Periodic breathing and sleep apnea.

Acetazolamide inhibits carbonic anhydrase, reducing bicarbonate reabsorption in the kidney and promoting diuresis and alkalinization of urine.

Acetazolamide inhibits carbonic anhydrase, reducing bicarbonate reabsorption in the kidney and promoting diuresis and alkalinization of urine. Used for Glaucoma and ocular hypertension, Acute mountain sickness, Periodic breathing and sleep apnea.

At a glance

Generic nameIntravenous acetazolamide
SponsorNational University Hospital, Singapore
Drug classCarbonic anhydrase inhibitor
TargetCarbonic anhydrase
ModalitySmall molecule
Therapeutic areaOphthalmology, Neurology, Nephrology
PhaseFDA-approved

Mechanism of action

Acetazolamide is a carbonic anhydrase inhibitor that decreases the conversion of carbon dioxide and water to bicarbonate and hydrogen ions in the proximal tubule of the kidney. This leads to increased urinary bicarbonate, sodium, and potassium excretion, resulting in mild diuresis and metabolic acidosis. The drug also reduces aqueous humor production in the eye and has effects on the central nervous system that may reduce periodic breathing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravenous acetazolamide

What is Intravenous acetazolamide?

Intravenous acetazolamide is a Carbonic anhydrase inhibitor drug developed by National University Hospital, Singapore, indicated for Glaucoma and ocular hypertension, Acute mountain sickness, Periodic breathing and sleep apnea.

How does Intravenous acetazolamide work?

Acetazolamide inhibits carbonic anhydrase, reducing bicarbonate reabsorption in the kidney and promoting diuresis and alkalinization of urine.

What is Intravenous acetazolamide used for?

Intravenous acetazolamide is indicated for Glaucoma and ocular hypertension, Acute mountain sickness, Periodic breathing and sleep apnea, Idiopathic intracranial hypertension.

Who makes Intravenous acetazolamide?

Intravenous acetazolamide is developed and marketed by National University Hospital, Singapore (see full National University Hospital, Singapore pipeline at /company/national-university-hospital-singapore).

What drug class is Intravenous acetazolamide in?

Intravenous acetazolamide belongs to the Carbonic anhydrase inhibitor class. See all Carbonic anhydrase inhibitor drugs at /class/carbonic-anhydrase-inhibitor.

What development phase is Intravenous acetazolamide in?

Intravenous acetazolamide is FDA-approved (marketed).

What are the side effects of Intravenous acetazolamide?

Common side effects of Intravenous acetazolamide include Paresthesia (tingling in extremities), Metabolic acidosis, Hypokalemia, Altered taste (dysgeusia), Nausea, Headache.

What does Intravenous acetazolamide target?

Intravenous acetazolamide targets Carbonic anhydrase and is a Carbonic anhydrase inhibitor.

Related